

WHAT IS CLAIMED IS:

- 5 1. A process for stabilizing a blood protein solution comprising:
(a) providing a blood protein solution;
(b) adding to the solution hydroxypropyl- α -cyclodextrin in an amount
sufficient to form a stable complex with the protein; and
(c) lyophilizing the solution of step (b) to form a lyophilized
10 protein/hydroxypropyl- α -cyclodextrin complex.
2. The process according to claim 1, further comprising reconstituting the
lyophilized protein/hydroxypropyl- α -cyclodextrin complex.
- 15 3. The process according to claim 1, further comprising heating the blood protein
solution, before or after adding hydroxypropyl- α -cyclodextrin, at least about 60°C for a time
sufficient to inactivate any viruses present in the protein/hydroxypropyl- α -cyclodextrin complex.
- 20 4. The process according to claim 3 wherein the blood protein solution is heated for
at least about 10 hours.
5. The process according to claim 3 wherein the blood protein solution is heated to
a temperature of at least about 80°C for at least about 72 hours.
- 25 6. The process according to claim 3 wherein the blood protein solution is heated to
about 100°C for at least about 1 hour.
7. The process according to claim 1, further comprising subjecting the blood protein
solution, before or after adding the hydroxypropyl- α -cyclodextrin, to a solvent detergent viral
30 inactivation step.
8. The process according to claim 1, wherein the hydroxypropyl- α -cyclodextrin is
present in the protein solution in an amount ranging from about 0.5% wt/vol. to about 15%
wt/vol.

1 32943/KMO/A97

9. The process according to claim 1, wherein the hydroxypropyl- α -cyclodextrin is present in the protein solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.

5

10. The process according to claim 2, wherein the protein is present in the reconstituted protein/hydroxypropyl- α -cyclodextrin complex in an amount greater than about 0.1% wt/vol.

10

11. The process according to claim 2 wherein the protein is present in the reconstituted protein /hydroxypropyl- α -cyclodextrin complex in an amount from about 1% to about 8 %.

15

12. The process according to claim 1 wherein the protein is selected from the group consisting of albumin, Factor II, Factor VII, Factor VIII, Factor IX, Factors X and X_a, fibrinogen, antithrombin III, transferrin, haptoglobin, gamma globulins, fibronectin, protein C, protein S, thrombin and C1-inhibitor.

20

13. The process according to claim 1, wherein the protein is fibrinogen.

25

14. The process according to claim 12, wherein the hydroxypropyl- α -cyclodextrin is present in the protein solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.

15. The process according to claim 12, wherein the hydroxypropyl- α -cyclodextrin is present in the protein solution in an amount ranging from about 2% wt/vol. to about 12% wt/vol.

30

16. The process according to claim 12, wherein the fibrinogen is present in the reconstituted protein/hydroxypropyl- α -cyclodextrin complex in an amount greater than about 1% wt/vol.

35

17. The process according to claim 12, wherein the protein is fibrinogen, and the fibrinogen is present in the reconstituted protein /hydroxypropyl- α -cyclodextrin complex in an amount from about 3% wt/vol. to about 10% wt/vol.

18. A process for stabilizing a fibrinogen solution comprising:
- (a) providing a fibrinogen solution;
 - 5 (b) adding to the solution hydroxypropyl- α -cyclodextrin in an amount sufficient to form a stable complex with the protein;
 - (c) lyophilizing the solution of step (b) to form a lyophilized fibrinogen/hydroxypropyl- α -cyclodextrin complex; and
 - (d) reconstituting the lyophilized fibrinogen/hydroxypropyl- α -cyclodextrin
 - 10 complex.

19. A lyophilized blood protein/hydroxypropyl- α -cyclodextrin complex prepared by:
- (a) providing a blood protein solution;
 - (b) adding to the solution hydroxypropyl- α -cyclodextrin in an amount
 - 15 sufficient to form a stable complex with the protein; and
 - (c) lyophilizing the solution of step (b) to form the lyophilized blood protein/hydroxypropyl- α -cyclodextrin complex.

20. A blood protein product prepared by:
- (a) providing a blood protein solution;
 - (b) adding to the solution hydroxypropyl- α -cyclodextrin in an amount
 - 20 sufficient to form a stable complex with the protein;
 - (c) lyophilizing the solution of step (b) to form a lyophilized protein/hydroxypropyl- α -cyclodextrin complex; and
 - (d) reconstituting the lyophilized protein/hydroxypropyl- α -cyclodextrin
 - 25 complex.

21. A fibrinogen product prepared by:
- (a) providing a fibrinogen solution;
 - 30 (b) adding to the solution hydroxypropyl- α -cyclodextrin in an amount sufficient to form a stable complex with the protein;
 - (c) lyophilizing the solution of step (b) to form a lyophilized fibrinogen/hydroxypropyl- α -cyclodextrin complex; and
 - (d) reconstituting the lyophilized fibrinogen/hydroxypropyl- α -cyclodextrin
 - 35 complex.

1 32943/KMO/A97

22. A blood protein product comprising a lyophilized solution of a stable complex of protein and hydroxypropyl- α -cyclodextrin.

5

23. The product according to claim 22, wherein the hydroxypropyl- α -cyclodextrin is present in the solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.

10

24. The product according to claim 22, wherein the hydroxypropyl- α -cyclodextrin is present in the solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.

25. The product according to claim 22, wherein the blood protein is fibrinogen.

15

26. A stabilized blood protein solution comprising a complex of the blood protein and hydroxypropyl- α -cyclodextrin.

27. The solution according to claim 26, wherein the protein is present in the complex in an amount greater than about 3% wt/vol.

20

28. The product according to claim 26, wherein the hydroxypropyl- α -cyclodextrin is present in the solution in an amount ranging from about 0.5% wt/vol. to about 15% wt/vol.

29. The process according to claim 26, wherein the hydroxypropyl- α -cyclodextrin is present in the solution in an amount ranging from about 1% wt/vol. to about 12% wt/vol.

25

30. The product according to claim 26, wherein the blood protein is fibrinogen.

30

35